MediBIC Group is a Japan-based company comprised of four business segments. The Biomarker Drug Discovery segment provides total support solution services, including development strategy planning consulting, data analysis and new-drug application support, to pharmacogenomics (PGx) tests. This segment also provides technology analytical services and software, as well as selling research support products. The Drug Discovery segment adds value to candidate compounds of genomic, advanced and general new drugs to acquire part of intellectual properties. The Investment and Incubation segment invests mainly in life science companies, and sells investees' products. The Others segment is engaged in the holding of seminars and forums for researchers. MediBIC has three subsidiaries. The Company acquired its affiliated company, Asia Private Equity Capital on October 1, 2008.
Biotron Limited (Biotron) is an Australia-based company. The principal activities of the Company are funding and management of intermediate and applied biotechnology research and development projects. During the fiscal year ended June 30, 2008 (fiscal 2008), the Company completed the Phase I clinical trial of the Company’s antiviral drug BIT225. BIT225 is an investigational, orally-administered, antiviral compound in development by Biotron for treatment of Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) infections. (Source: ARS)
Echelon Biosciences Inc., a Salt Lake City based biotechnology company with 20 employees, is engaged in furthering the science of lipid cell signalling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease. The focus is also on small molecule agonists and antagonists to lipid-protein signalling interactions which are new and important therapeutic targets. Furthermore, Echelon markets chemical reagents.
PainCeptor Pharma is a biopharmaceutical company developing next generation therapeutic drugs for the treatment of chronic and acute pain.
PharmaGap Inc. is a development stage company, principally engaged in drug development and out-licensing of drug compounds. It is a biotechnology company with the main focus on designing and developing therapeutic drugs for the treatment of cancer and other human diseases associated with the human Protein Kinase C enzyme (PKC). Using its drug development platform, the Company is developing a pipeline of compounds targeting PKC. PKC is expressed in abnormal levels in many types of cancer and other diseases, such as diabetes. As of December 31, 2007, the Company’s lead drug compound, PhGa1, was in the pre-clinical testing stage, and had shown in vitro and in vivo efficacy in selected cancer types. (Source: ARS)
RiboTargets is a privately owned pharmaceutical drug discovery company focused on the development of novel anti-bacterial and anti-cancer therapeutics. These therapeutic areas represent significant market opportunities. The Company has created and validated a proprietary structure-based drug discovery engine that allows the rapid identification and optimisation of drug candidates against both protein and nucleic acid targets using high throughput computer-aided and experimental drug design. Over the last four years, RiboTargets has made the transition from a technology platform company into a competitive drug discovery company. RiboTargets' goal for 2003 is to make the pivotal step from research into formal drug development. In the longer term, RiboTargets aims to become a significant player in the anti-bacterial and anti-cancer markets.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory